☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
immunotherapies
Gilead Signs an Option and License Agreement with Gritstone for HIV Vaccine
February 2, 2021
Eisai Signs a Research and Option Agreement with Numab to Discover and Develop Multi-Specific Antibody Immunotherapies for Cancer
October 1, 2019
Thyas Signs an Exclusive License Agreement with iPS Academia Japan (iPS-AJ) to Develop Autologous Immunotherapies
January 18, 2019
Eli Lilly Collaborates with Aduro Biotech for its cGAS-STING Pathway Inhibitor Program to Develop Immunotherapies
December 19, 2018
Leidos Collaborates with GeoVax for the Development of Immunotherapies for Cancer
November 20, 2018
Load more...
Back to Home